Novartis elects to keep one heart drug, discard the other from option deal with Akcea, Ionis
One heart drug is enough, Novartis has signaled to Akcea.
The Swiss drugmaker tied up with the antisense company, and close affiliate Ionis, in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
